<DOC>
	<DOCNO>NCT00490763</DOCNO>
	<brief_summary>The goal clinical research study find men type prostate cancer classify `` low risk '' safely treat disease . Doctors want know patient `` low risk '' cancer avoid postpone therapy related side effect still live long patient immediately receive therapy .</brief_summary>
	<brief_title>Active Surveillance Prostate Cancer</brief_title>
	<detailed_description>You early stage prostate cancer treat effectively surgery radiation . If choose take part study , agree receive active surveillance . Active surveillance investigational way manage low-stage small volume prostate cancer . While active surveillance , treatment prostate cancer . However , repeat Prostate Specific Antigen ( PSA ) test , physical exam , test detect cancer become great risk may require begin treatment . If agree participate study , standard therapy prostate cancer . Your diagnosis confirm low risk test MD Anderson . Blood drawn PSA test begin study every 6 month monitor cancer . You biopsy prostate beginning study . Additional prostate biopsy perform first repeat biopsy Year 1 , doctor think necessary . You digital rectal examination every 6 month see doctor feel prostate nodule . You transrectal ultrasonography every 12 month see doctor detect abnormality prostate . Additionally , fill 7 survey begin study every 6 month cop disease quality life . Each survey take 5 10 minute complete . While study , exam test result show disease get worse , give opportunity treatment remove cancer . If choose receive treatment , take study continue receive standard follow-up . Long-Term Follow-Up : Every 12 month , study staff review medical record call e-mailed asked . If call , call would last minute . This investigational study . About 1,000 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patients histologic proof adenocarcinoma prostate within six month study entry . 2 . Patients must agree repeat extend 11core multisite biopsy ( sextant location , midline , 2 core leave right anterior horn ) prostate study entry . A baseline prostate biopsy indicate repeat biopsy follow extend biopsy scheme ( least 10 biopsy core ) perform The University Texas M. D. Anderson Cancer Center ( MDACC ) within 6 month study entry . 3 . Patients clinically localized cancer define pathologic PSA criterion lowrisk/lowrisk , patient clinically localized cancer [ lowrisk ] refuse early intervention choose active surveillance management option , patient clinically localized cancer preclude local therapy comorbidities . 4 . Patients must agree comply surveillance schedule . 5 . NonEnglish speaking patient may participate study , require complete survey . 6 . Patients must sign informed consent indicate aware investigational nature study . 1 . Active noncutaneous malignancy site . 2 . Prior radiation therapy treatment primary tumor . 3 . Planned concomitant immunotherapy , hormonal therapy , chemotherapy , radiation therapy protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Active Surveillance</keyword>
	<keyword>Prostate Specific Antigen</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>